CD274 and neoplasm: PD-L1 status on tumor tissue has been shown to be an imperfect predictive biomarker and, despite the intensive effort, reproducible and dynamic biomarkers to select those patients who are most likely to have a good immunotherapy response have not yet been developed for therapeutic decisions [6].